Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl
- PMID: 16481037
- DOI: 10.1016/j.leukres.2006.01.005
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl
Erratum in
-
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272].Leuk Res. 2019 Jul;82:46-47. doi: 10.1016/j.leukres.2019.03.002. Epub 2019 May 10. Leuk Res. 2019. PMID: 31079870 No abstract available.
Abstract
Effects of the tyrphostin adaphostin and bortezomib were examined in Bcr/Abl+ leukemia cell resistant to imatinib mesylate secondary to Bcr/Abl point mutations. Adaphostin was equally effective in inducing mitochondrial damage, caspase activation, JNK activation, and Raf-1, phospho-Stat3 and -Stat5 inactivation in mutant and wild-type cells, but differentially down-regulated phospho-Bcr/Abl. Adaphostin and bortezomib synergistically induced apoptosis in wild-type and mutant cells, including T315I mutants. Notably, adaphostin+/-bortezomib potently induced ROS and lethality in mutant cells, effects attenuated by the antioxidant NAC. These findings indicate that adaphostin+/-bortezomib circumvent imatinib resistance due to Bcr/Abl point mutations most likely through ROS generation.
Comment in
-
Findings of Research Misconduct.NIH Guide Grants Contracts (Bethesda). 2015 Dec 18:NOT-OD-16-040. NIH Guide Grants Contracts (Bethesda). 2015. PMID: 26693581 Free PMC article. No abstract available.
-
Findings of Research Misconduct.Fed Regist. 2015 Dec 10;80(237):76703-76704. Fed Regist. 2015. PMID: 27737268 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
